Valuation: GlaxoSmithKline Pharmaceuticals Limited

Market Cap 469B 4.89B 4.32B 4.09B 3.69B 6.96B 7.05B 48.96B 18.82B 240B 18.37B 17.97B 770B P/E 2027 *
40.2x
P/E 2028 * 35x
Enterprise Value 469B 4.89B 4.32B 4.09B 3.69B 6.96B 7.05B 48.96B 18.82B 240B 18.37B 17.97B 770B EV / Sales 2027 *
11x
EV / Sales 2028 * 9.92x
Free-Float
24.37%
Yield 2027 *
1.07%
Yield 2028 * 1.07%

Last Transcript: GlaxoSmithKline Pharmaceuticals Limited

1 day-0.52%
1 week-3.63%
Current month-9.21%
1 month-10.85%
3 months+17.62%
6 months+22.56%
Current year+11.95%
1 week 2,752.1
Extreme 2752.1
2,987
1 month 2,752.1
Extreme 2752.1
3,120
Current year 2,088.1
Extreme 2088.1
3,120.7
1 year 2,088.1
Extreme 2088.1
3,120.7
3 years 1,385.05
Extreme 1385.05
3,515.7
5 years 1,227
Extreme 1227
3,515.7
10 years 962.65
Extreme 962.65
3,515.7
Manager TitleAgeSince
Chief Executive Officer 56 30/11/2022
Director of Finance/CFO - 31/03/2026
Chief Tech/Sci/R&D Officer - 07/07/2024
Director TitleAgeSince
Chairman 73 31/03/2019
Director/Board Member 59 17/05/2020
Director/Board Member 67 15/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-3.63% - - 4.92B
-2.33%-1.12%+59.27%+115.42% 1,056B
-1.06%-1.65%+45.77%+69.98% 645B
-0.65%-1.36%+17.22%+75.49% 465B
-2.66%-3.71%+84.92%+41.15% 368B
-0.06%-4.12%+36.31%+39.39% 335B
-0.79%+3.01%+21.11%+27.79% 275B
-1.19%-3.09%+10.75%+10.61% 255B
-0.50%+2.75%+53.85%+56.84% 229B
-1.47%-2.37%+32.35%+98.89% 188B
Average -0.09%+0.12%+40.17%+59.51% 423.98B
Weighted average by Cap. +0.47%+0.30%+44.68%+71.39%

Financials

2027 *2028 *
Net sales 42.57B 444M 392M 371M 335M 632M 640M 4.45B 1.71B 21.78B 1.67B 1.63B 69.91B 47.24B 493M 435M 412M 372M 702M 710M 4.93B 1.9B 24.17B 1.85B 1.81B 77.59B
Net income 11.65B 122M 107M 102M 91.7M 173M 175M 1.22B 468M 5.96B 457M 447M 19.14B 13.42B 140M 124M 117M 106M 199M 202M 1.4B 539M 6.86B 526M 514M 22.04B
Net Debt - -
Logo GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Employees
3,103
Date Price Change Volume
30/09/26 ₹2,769.30 -0.52% 45,801
29/09/26 ₹2,783.80 -3.89% 49,829
28/09/26 ₹2,896.40 +2.87% 459,963
25/09/26 ₹2,815.70 -0.48% 15,380
24/09/26 ₹2,829.20 -1.66% 17,953
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,767.60INR
Average target price
3,081.00INR
Spread / Average Target
+11.32%

Quarterly revenue - Rate of surprise